#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2 .
1-1	0-1	2	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=The Role of the bHLH Proteins in Transcription
2-1	4-7	The	abstract[2]	new[2]	_	_
2-2	8-12	Role	abstract[2]	new[2]	_	_
2-3	13-15	of	abstract[2]	new[2]	_	_
2-4	16-19	the	abstract[2]|substance[4]	new[2]|new[4]	coref	5-11[0_4]
2-5	20-24	bHLH	abstract[2]|abstract|substance[4]	new[2]|new|new[4]	coref	8-7
2-6	25-33	Proteins	abstract[2]|substance[4]	new[2]|new[4]	_	_
2-7	34-36	in	abstract[2]|substance[4]	new[2]|new[4]	_	_
2-8	37-50	Transcription	abstract[2]|substance[4]|abstract	new[2]|new[4]|new	coref	3-8

#Text=The regulation of genes expression by multiple transcription factors , cofactors and chromatin regulators establish and maintains a specific state of a cell .
3-1	51-54	The	abstract[6]	new[6]	_	_
3-2	55-65	regulation	abstract[6]	new[6]	_	_
3-3	66-68	of	abstract[6]	new[6]	_	_
3-4	69-74	genes	abstract[6]|abstract	new[6]|new	coref	12-18[98_0]
3-5	75-85	expression	_	_	_	_
3-6	86-88	by	_	_	_	_
3-7	89-97	multiple	abstract[9]	new[9]	_	_
3-8	98-111	transcription	abstract|abstract[9]	giv|new[9]	coref	5-3
3-9	112-119	factors	abstract[9]	new[9]	_	_
3-10	120-121	,	_	_	_	_
3-11	122-131	cofactors	person	new	_	_
3-12	132-135	and	_	_	_	_
3-13	136-145	chromatin	substance|substance[12]	new|new[12]	coref|coref	8-18|8-18
3-14	146-156	regulators	substance[12]	new[12]	_	_
3-15	157-166	establish	_	_	_	_
3-16	167-170	and	_	_	_	_
3-17	171-180	maintains	_	_	_	_
3-18	181-182	a	abstract[13]	new[13]	_	_
3-19	183-191	specific	abstract[13]	new[13]	_	_
3-20	192-197	state	abstract[13]	new[13]	_	_
3-21	198-200	of	abstract[13]	new[13]	_	_
3-22	201-202	a	abstract[13]|place[14]	new[13]|new[14]	coref	15-10[0_14]
3-23	203-207	cell	abstract[13]|place[14]	new[13]|new[14]	_	_
3-24	208-209	.	_	_	_	_

#Text=Inaccurate regulation of transmitted signals can results in diseases and severe disorders .
4-1	210-220	Inaccurate	abstract[15]	new[15]	coref	9-12[55_15]
4-2	221-231	regulation	abstract[15]	new[15]	_	_
4-3	232-234	of	abstract[15]	new[15]	_	_
4-4	235-246	transmitted	abstract[15]|abstract[16]	new[15]|new[16]	_	_
4-5	247-254	signals	abstract[15]|abstract[16]	new[15]|new[16]	_	_
4-6	255-258	can	_	_	_	_
4-7	259-266	results	abstract[17]	new[17]	_	_
4-8	267-269	in	abstract[17]	new[17]	_	_
4-9	270-278	diseases	abstract[17]|abstract	new[17]|new	_	_
4-10	279-282	and	abstract[17]	new[17]	_	_
4-11	283-289	severe	abstract[17]|abstract[19]	new[17]|new[19]	_	_
4-12	290-299	disorders	abstract[17]|abstract[19]	new[17]|new[19]	_	_
4-13	300-301	.	_	_	_	_

#Text=Therefore , transcription requires balanced orchestration of adjustable complexes of proteins .
5-1	302-311	Therefore	_	_	_	_
5-2	312-313	,	_	_	_	_
5-3	314-327	transcription	abstract	giv	coref	6-5
5-4	328-336	requires	_	_	_	_
5-5	337-345	balanced	abstract[21]	new[21]	_	_
5-6	346-359	orchestration	abstract[21]	new[21]	_	_
5-7	360-362	of	abstract[21]	new[21]	_	_
5-8	363-373	adjustable	abstract[21]|abstract[22]	new[21]|new[22]	_	_
5-9	374-383	complexes	abstract[21]|abstract[22]	new[21]|new[22]	_	_
5-10	384-386	of	abstract[21]|abstract[22]	new[21]|new[22]	_	_
5-11	387-395	proteins	abstract[21]|abstract[22]|substance	new[21]|new[22]|giv	coref	11-1[79_0]
5-12	396-397	.	_	_	_	_

#Text=A key regulator of transcription is Mediator , a multi-subunit Mediator complex which interacts with RNA polymerase II ( Pol II ) , and coordinates the action of numerous co-activators and co-repressors .
6-1	398-399	A	person[24]	new[24]	coref	6-7[0_24]
6-2	400-403	key	person[24]	new[24]	_	_
6-3	404-413	regulator	person[24]	new[24]	_	_
6-4	414-416	of	person[24]	new[24]	_	_
6-5	417-430	transcription	person[24]|abstract	new[24]|giv	coref	9-12
6-6	431-433	is	_	_	_	_
6-7	434-442	Mediator	person	giv	coref	6-11
6-8	443-444	,	_	_	_	_
6-9	445-446	a	abstract[28]	new[28]	_	_
6-10	447-460	multi-subunit	abstract[28]	new[28]	_	_
6-11	461-469	Mediator	person|abstract[28]	giv|new[28]	coref	7-3[37_0]
6-12	470-477	complex	abstract[28]	new[28]	_	_
6-13	478-483	which	_	_	_	_
6-14	484-493	interacts	_	_	_	_
6-15	494-498	with	_	_	_	_
6-16	499-502	RNA	substance|abstract[30]	new|new[30]	_	_
6-17	503-513	polymerase	abstract[30]	new[30]	_	_
6-18	514-516	II	abstract[30]	new[30]	_	_
6-19	517-518	(	_	_	_	_
6-20	519-522	Pol	person	new	coref	26-26[221_0]
6-21	523-525	II	person	new	_	_
6-22	526-527	)	_	_	_	_
6-23	528-529	,	_	_	_	_
6-24	530-533	and	_	_	_	_
6-25	534-545	coordinates	_	_	_	_
6-26	546-549	the	abstract[33]	new[33]	_	_
6-27	550-556	action	abstract[33]	new[33]	_	_
6-28	557-559	of	abstract[33]	new[33]	_	_
6-29	560-568	numerous	abstract[33]|person[34]	new[33]|new[34]	_	_
6-30	569-582	co-activators	abstract[33]|person[34]	new[33]|new[34]	_	_
6-31	583-586	and	abstract[33]	new[33]	_	_
6-32	587-600	co-repressors	abstract[33]|person	new[33]|new	_	_
6-33	601-602	.	_	_	_	_

#Text=Function of the Mediator is conserved in all eukaryotes , though , the individual subunits have diverged considerably in some organisms .
7-1	603-611	Function	abstract[36]	new[36]	_	_
7-2	612-614	of	abstract[36]	new[36]	_	_
7-3	615-618	the	abstract[36]|person[37]	new[36]|giv[37]	coref	8-15[47_37]
7-4	619-627	Mediator	abstract[36]|person[37]	new[36]|giv[37]	_	_
7-5	628-630	is	_	_	_	_
7-6	631-640	conserved	_	_	_	_
7-7	641-643	in	_	_	_	_
7-8	644-647	all	place[38]	new[38]	_	_
7-9	648-658	eukaryotes	place[38]	new[38]	_	_
7-10	659-660	,	_	_	_	_
7-11	661-667	though	_	_	_	_
7-12	668-669	,	_	_	_	_
7-13	670-673	the	abstract[39]	new[39]	coref	8-13[46_39]
7-14	674-684	individual	abstract[39]	new[39]	_	_
7-15	685-693	subunits	abstract[39]	new[39]	_	_
7-16	694-698	have	_	_	_	_
7-17	699-707	diverged	_	_	_	_
7-18	708-720	considerably	_	_	_	_
7-19	721-723	in	_	_	_	_
7-20	724-728	some	animal[40]	new[40]	_	_
7-21	729-738	organisms	animal[40]	new[40]	_	_
7-22	739-740	.	_	_	_	_

#Text=Up to date , for some bHLH family representatives , interactions with subunits of the Mediator and/or chromatin remodeling histone acetyltransferases/deacyltransferase , were reported .
8-1	741-743	Up	_	_	_	_
8-2	744-746	to	_	_	_	_
8-3	747-751	date	time	new	_	_
8-4	752-753	,	_	_	_	_
8-5	754-757	for	_	_	_	_
8-6	758-762	some	person[44]	new[44]	_	_
8-7	763-767	bHLH	organization|person[44]	giv|new[44]	coref	10-46
8-8	768-774	family	abstract|person[44]	new|new[44]	coref	10-45[75_0]
8-9	775-790	representatives	person[44]	new[44]	_	_
8-10	791-792	,	_	_	_	_
8-11	793-805	interactions	abstract[45]	new[45]	coref	28-33[241_45]
8-12	806-810	with	abstract[45]	new[45]	_	_
8-13	811-819	subunits	abstract[45]|abstract[46]	new[45]|giv[46]	_	_
8-14	820-822	of	abstract[45]|abstract[46]	new[45]|giv[46]	_	_
8-15	823-826	the	abstract[45]|abstract[46]|person[47]	new[45]|giv[46]|giv[47]	coref	9-4[52_47]
8-16	827-835	Mediator	abstract[45]|abstract[46]|person[47]	new[45]|giv[46]|giv[47]	_	_
8-17	836-842	and/or	abstract[49]	new[49]	coref	18-17[0_49]
8-18	843-852	chromatin	substance|abstract[49]	giv|new[49]	coref	18-34
8-19	853-863	remodeling	abstract[49]	new[49]	_	_
8-20	864-871	histone	abstract[49]	new[49]	_	_
8-21	872-908	acetyltransferases/deacyltransferase	abstract[49]|substance	new[49]|new	_	_
8-22	909-910	,	_	_	_	_
8-23	911-915	were	_	_	_	_
8-24	916-924	reported	_	_	_	_
8-25	925-926	.	_	_	_	_

#Text=In plants , the Mediator complex is a core element of transcription regulation important for their immunity .
9-1	927-929	In	_	_	_	_
9-2	930-936	plants	plant	new	ana	9-16
9-3	937-938	,	_	_	_	_
9-4	939-942	the	person[52]	giv[52]	coref	10-28[67_52]
9-5	943-951	Mediator	person[52]	giv[52]	_	_
9-6	952-959	complex	person[52]	giv[52]	_	_
9-7	960-962	is	_	_	_	_
9-8	963-964	a	abstract[53]	new[53]	coref	11-1[77_53]
9-9	965-969	core	abstract[53]	new[53]	_	_
9-10	970-977	element	abstract[53]	new[53]	_	_
9-11	978-980	of	abstract[53]	new[53]	_	_
9-12	981-994	transcription	abstract[53]|abstract|abstract[55]	new[53]|giv|giv[55]	coref|coref	11-19|11-19
9-13	995-1005	regulation	abstract[53]|abstract[55]	new[53]|giv[55]	_	_
9-14	1006-1015	important	abstract[53]	new[53]	_	_
9-15	1016-1019	for	_	_	_	_
9-16	1020-1025	their	plant|abstract[57]	giv|new[57]	ana|ana	10-1[0_57]|10-1[0_57]
9-17	1026-1034	immunity	abstract[57]	new[57]	_	_
9-18	1035-1036	.	_	_	_	_

#Text=It was shown , that in Arabidopsis thaliana important jasmonate signaling and resistance to fungus Botrytis cinerea , is dependent on the interaction between MED25 subunit of the Mediator and MYC2 , and interaction of MED8 subunit of the Mediator with FAMA belonging to the bHLH family .
10-1	1037-1039	It	abstract	giv	_	_
10-2	1040-1043	was	_	_	_	_
10-3	1044-1049	shown	_	_	_	_
10-4	1050-1051	,	_	_	_	_
10-5	1052-1056	that	_	_	_	_
10-6	1057-1059	in	_	_	_	_
10-7	1060-1071	Arabidopsis	abstract	new	_	_
10-8	1072-1080	thaliana	abstract[61]	new[61]	_	_
10-9	1081-1090	important	abstract[61]	new[61]	_	_
10-10	1091-1100	jasmonate	abstract|abstract[61]	new|new[61]	_	_
10-11	1101-1110	signaling	abstract[61]	new[61]	_	_
10-12	1111-1114	and	_	_	_	_
10-13	1115-1125	resistance	abstract[62]	new[62]	_	_
10-14	1126-1128	to	abstract[62]	new[62]	_	_
10-15	1129-1135	fungus	abstract[62]|plant	new[62]|new	_	_
10-16	1136-1144	Botrytis	_	_	_	_
10-17	1145-1152	cinerea	_	_	_	_
10-18	1153-1154	,	_	_	_	_
10-19	1155-1157	is	_	_	_	_
10-20	1158-1167	dependent	_	_	_	_
10-21	1168-1170	on	_	_	_	_
10-22	1171-1174	the	abstract[64]	new[64]	coref	21-6[179_64]
10-23	1175-1186	interaction	abstract[64]	new[64]	_	_
10-24	1187-1194	between	abstract[64]	new[64]	_	_
10-25	1195-1200	MED25	abstract[64]|abstract|abstract[66]	new[64]|new|new[66]	_	_
10-26	1201-1208	subunit	abstract[64]|abstract[66]	new[64]|new[66]	_	_
10-27	1209-1211	of	abstract[64]|abstract[66]	new[64]|new[66]	_	_
10-28	1212-1215	the	abstract[64]|abstract[66]|person[67]	new[64]|new[66]|giv[67]	coref	10-39[72_67]
10-29	1216-1224	Mediator	abstract[64]|abstract[66]|person[67]	new[64]|new[66]|giv[67]	_	_
10-30	1225-1228	and	abstract[64]|abstract[66]	new[64]|new[66]	_	_
10-31	1229-1233	MYC2	abstract[64]|abstract[66]|object	new[64]|new[66]|new	_	_
10-32	1234-1235	,	_	_	_	_
10-33	1236-1239	and	_	_	_	_
10-34	1240-1251	interaction	abstract[69]	new[69]	_	_
10-35	1252-1254	of	abstract[69]	new[69]	_	_
10-36	1255-1259	MED8	abstract[69]|abstract|organization[71]	new[69]|new|new[71]	_	_
10-37	1260-1267	subunit	abstract[69]|organization[71]	new[69]|new[71]	_	_
10-38	1268-1270	of	abstract[69]|organization[71]	new[69]|new[71]	_	_
10-39	1271-1274	the	abstract[69]|organization[71]|person[72]	new[69]|new[71]|giv[72]	coref	12-14[97_72]
10-40	1275-1283	Mediator	abstract[69]|organization[71]|person[72]	new[69]|new[71]|giv[72]	_	_
10-41	1284-1288	with	abstract[69]|organization[71]|person[72]	new[69]|new[71]|giv[72]	_	_
10-42	1289-1293	FAMA	abstract[69]|organization[71]|person[72]|abstract	new[69]|new[71]|giv[72]|new	_	_
10-43	1294-1303	belonging	_	_	_	_
10-44	1304-1306	to	_	_	_	_
10-45	1307-1310	the	abstract[75]	giv[75]	_	_
10-46	1311-1315	bHLH	person|abstract[75]	giv|giv[75]	coref	11-12
10-47	1316-1322	family	abstract[75]	giv[75]	_	_
10-48	1323-1324	.	_	_	_	_

#Text=Sterol regulatory element binding proteins ( SREBPs ) the class II bHLH TFs ( Table 1 ) are transcription activators critical for regulation of cholesterol and fatty acid homeostasis in animals .
11-1	1325-1331	Sterol	abstract|abstract[77]|substance[79]	new|giv[77]|giv[79]	coref|coref|coref	11-19[85_79]|11-19[85_79]|11-19[85_79]
11-2	1332-1342	regulatory	abstract[77]|substance[79]	giv[77]|giv[79]	_	_
11-3	1343-1350	element	abstract[77]|substance[79]	giv[77]|giv[79]	_	_
11-4	1351-1358	binding	object|substance[79]	new|giv[79]	_	_
11-5	1359-1367	proteins	substance[79]	giv[79]	_	_
11-6	1368-1369	(	_	_	_	_
11-7	1370-1376	SREBPs	object	new	coref	12-5[92_0]
11-8	1377-1378	)	_	_	_	_
11-9	1379-1382	the	abstract[81]	new[81]	coref	18-41[148_81]
11-10	1383-1388	class	abstract[81]	new[81]	_	_
11-11	1389-1391	II	_	_	_	_
11-12	1392-1396	bHLH	abstract	giv	coref	28-11
11-13	1397-1400	TFs	_	_	_	_
11-14	1401-1402	(	_	_	_	_
11-15	1403-1408	Table	object	new	coref	14-9[109_0]
11-16	1409-1410	1	_	_	_	_
11-17	1411-1412	)	_	_	_	_
11-18	1413-1416	are	_	_	_	_
11-19	1417-1430	transcription	abstract|substance[85]	giv|giv[85]	coref|coref|coref|coref	23-5[0_85]|23-19|23-5[0_85]|23-19
11-20	1431-1441	activators	substance[85]	giv[85]	_	_
11-21	1442-1450	critical	substance[85]	giv[85]	_	_
11-22	1451-1454	for	_	_	_	_
11-23	1455-1465	regulation	abstract[86]	new[86]	_	_
11-24	1466-1468	of	abstract[86]	new[86]	_	_
11-25	1469-1480	cholesterol	abstract[86]|substance	new[86]|new	_	_
11-26	1481-1484	and	abstract[86]	new[86]	_	_
11-27	1485-1490	fatty	abstract[86]|abstract[89]	new[86]|new[89]	ana	12-1[0_89]
11-28	1491-1495	acid	abstract[86]|substance|abstract[89]	new[86]|new|new[89]	_	_
11-29	1496-1507	homeostasis	abstract[86]|abstract[89]	new[86]|new[89]	_	_
11-30	1508-1510	in	abstract[86]|abstract[89]	new[86]|new[89]	_	_
11-31	1511-1518	animals	abstract[86]|abstract[89]|animal	new[86]|new[89]|new	_	_
11-32	1519-1520	.	_	_	_	_

#Text=It was shown that human SREBPs bind CBP/p300 acetyltransferase and MED15 subunit of the Mediator to activate target genes .
12-1	1521-1523	It	abstract	giv	_	_
12-2	1524-1527	was	_	_	_	_
12-3	1528-1533	shown	_	_	_	_
12-4	1534-1538	that	_	_	_	_
12-5	1539-1544	human	object[92]	giv[92]	_	_
12-6	1545-1551	SREBPs	object[92]	giv[92]	_	_
12-7	1552-1556	bind	_	_	_	_
12-8	1557-1565	CBP/p300	abstract|object[94]	new|new[94]	coref|coref|coref|coref	17-4|17-4[131_94]|17-4|17-4[131_94]
12-9	1566-1583	acetyltransferase	object[94]	new[94]	_	_
12-10	1584-1587	and	_	_	_	_
12-11	1588-1593	MED15	time|organization[96]	new|new[96]	coref|coref	13-8|13-8
12-12	1594-1601	subunit	organization[96]	new[96]	_	_
12-13	1602-1604	of	organization[96]	new[96]	_	_
12-14	1605-1608	the	organization[96]|organization[97]	new[96]|giv[97]	coref	13-12[0_97]
12-15	1609-1617	Mediator	organization[96]|organization[97]	new[96]|giv[97]	_	_
12-16	1618-1620	to	_	_	_	_
12-17	1621-1629	activate	_	_	_	_
12-18	1630-1636	target	abstract[98]	giv[98]	_	_
12-19	1637-1642	genes	abstract[98]	giv[98]	_	_
12-20	1643-1644	.	_	_	_	_

#Text=Also yeast Ino2 was shown to bind MED15 subunit of the Mediator tail .
13-1	1645-1649	Also	_	_	_	_
13-2	1650-1655	yeast	substance|abstract[100]	new|new[100]	_	_
13-3	1656-1660	Ino2	abstract[100]	new[100]	_	_
13-4	1661-1664	was	_	_	_	_
13-5	1665-1670	shown	_	_	_	_
13-6	1671-1673	to	_	_	_	_
13-7	1674-1678	bind	_	_	_	_
13-8	1679-1684	MED15	time|object[102]	giv|new[102]	_	_
13-9	1685-1692	subunit	object[102]	new[102]	_	_
13-10	1693-1695	of	object[102]	new[102]	_	_
13-11	1696-1699	the	object[102]|object[104]	new[102]|new[104]	_	_
13-12	1700-1708	Mediator	object[102]|person|object[104]	new[102]|giv|new[104]	_	_
13-13	1709-1713	tail	object[102]|object[104]	new[102]|new[104]	_	_
13-14	1714-1715	.	_	_	_	_

#Text=The representative of class II TFs TAL1 ( Table 1 ) is required for the specification of the blood lineage and maturation of several hematopoietic cells .
14-1	1716-1719	The	person[105]	new[105]	_	_
14-2	1720-1734	representative	person[105]	new[105]	_	_
14-3	1735-1737	of	person[105]	new[105]	_	_
14-4	1738-1743	class	person[105]|person[106]	new[105]|new[106]	_	_
14-5	1744-1746	II	person[105]|person[106]	new[105]|new[106]	_	_
14-6	1747-1750	TFs	abstract|abstract[108]	new|new[108]	coref|coref|coref|coref	16-3[125_0]|17-1[0_108]|16-3[125_0]|17-1[0_108]
14-7	1751-1755	TAL1	abstract[108]	new[108]	_	_
14-8	1756-1757	(	_	_	_	_
14-9	1758-1763	Table	object[109]	giv[109]	coref	18-44[150_109]
14-10	1764-1765	1	object[109]	giv[109]	_	_
14-11	1766-1767	)	_	_	_	_
14-12	1768-1770	is	_	_	_	_
14-13	1771-1779	required	_	_	_	_
14-14	1780-1783	for	_	_	_	_
14-15	1784-1787	the	abstract[110]	new[110]	_	_
14-16	1788-1801	specification	abstract[110]	new[110]	_	_
14-17	1802-1804	of	abstract[110]	new[110]	_	_
14-18	1805-1808	the	abstract[110]|abstract[112]	new[110]|new[112]	_	_
14-19	1809-1814	blood	abstract[110]|substance|abstract[112]	new[110]|new|new[112]	_	_
14-20	1815-1822	lineage	abstract[110]|abstract[112]	new[110]|new[112]	_	_
14-21	1823-1826	and	abstract[110]	new[110]	_	_
14-22	1827-1837	maturation	abstract[110]|event[113]	new[110]|new[113]	_	_
14-23	1838-1840	of	abstract[110]|event[113]	new[110]|new[113]	_	_
14-24	1841-1848	several	abstract[110]|event[113]|object[114]	new[110]|new[113]|new[114]	coref	15-18[122_114]
14-25	1849-1862	hematopoietic	abstract[110]|event[113]|object[114]	new[110]|new[113]|new[114]	_	_
14-26	1863-1868	cells	abstract[110]|event[113]|object[114]	new[110]|new[113]|new[114]	_	_
14-27	1869-1870	.	_	_	_	_

#Text=TAL1/SCL is considered as a master TF delineating the cell fate and the identity of progenitor and normal hematopoietic stem cells ( HSCs ) .
15-1	1871-1879	TAL1/SCL	abstract	new	_	_
15-2	1880-1882	is	_	_	_	_
15-3	1883-1893	considered	_	_	_	_
15-4	1894-1896	as	_	_	_	_
15-5	1897-1898	a	abstract[116]	new[116]	_	_
15-6	1899-1905	master	abstract[116]	new[116]	_	_
15-7	1906-1908	TF	abstract[116]	new[116]	_	_
15-8	1909-1920	delineating	_	_	_	_
15-9	1921-1924	the	abstract[118]	new[118]	_	_
15-10	1925-1929	cell	place|abstract[118]	giv|new[118]	coref	16-11
15-11	1930-1934	fate	abstract[118]	new[118]	_	_
15-12	1935-1938	and	_	_	_	_
15-13	1939-1942	the	abstract[119]	new[119]	_	_
15-14	1943-1951	identity	abstract[119]	new[119]	_	_
15-15	1952-1954	of	abstract[119]	new[119]	_	_
15-16	1955-1965	progenitor	abstract[119]|person	new[119]|new	_	_
15-17	1966-1969	and	abstract[119]	new[119]	_	_
15-18	1970-1976	normal	abstract[119]|object[122]	new[119]|giv[122]	_	_
15-19	1977-1990	hematopoietic	abstract[119]|object[122]	new[119]|giv[122]	_	_
15-20	1991-1995	stem	abstract[119]|plant|object[122]	new[119]|new|giv[122]	_	_
15-21	1996-2001	cells	abstract[119]|object[122]	new[119]|giv[122]	_	_
15-22	2002-2003	(	_	_	_	_
15-23	2004-2008	HSCs	place	new	ana	16-1
15-24	2009-2010	)	_	_	_	_
15-25	2011-2012	.	_	_	_	_

#Text=It regulates other hematopoietic TFs thus has a potential for cell reprogramming .
16-1	2013-2015	It	place	giv	_	_
16-2	2016-2025	regulates	_	_	_	_
16-3	2026-2031	other	abstract[125]	giv[125]	coref	18-64[0_125]
16-4	2032-2045	hematopoietic	abstract[125]	giv[125]	_	_
16-5	2046-2049	TFs	abstract[125]	giv[125]	_	_
16-6	2050-2054	thus	_	_	_	_
16-7	2055-2058	has	_	_	_	_
16-8	2059-2060	a	abstract[126]	new[126]	_	_
16-9	2061-2070	potential	abstract[126]	new[126]	_	_
16-10	2071-2074	for	abstract[126]	new[126]	_	_
16-11	2075-2079	cell	abstract[126]|place|abstract[128]	new[126]|giv|new[128]	coref|coref	20-3|20-3
16-12	2080-2093	reprogramming	abstract[126]|abstract[128]	new[126]|new[128]	_	_
16-13	2094-2095	.	_	_	_	_

#Text=TAL1 also binds CBP/p300 acetyltransferase .
17-1	2096-2100	TAL1	abstract	giv	_	_
17-2	2101-2105	also	_	_	_	_
17-3	2106-2111	binds	_	_	_	_
17-4	2112-2120	CBP/p300	abstract|substance[131]	giv|giv[131]	coref|coref	18-17[139_131]|18-17[139_131]
17-5	2121-2138	acetyltransferase	substance[131]	giv[131]	_	_
17-6	2139-2140	.	_	_	_	_

#Text=Similarly MyoD — a myogenic regulatory factor which controls skeletal muscle development binds CBP and recruits histone acetyltransferase to activate myogenic program . Cao et al. showed that of MyoD modify the myoblasts chromatin structure and accessibility . ASCL1 ( class II , Table 1 ) was shown to be a pioneer factor which promotes chromatin accessibility and enables chromatin binding by others TFs .
18-1	2141-2150	Similarly	_	_	_	_
18-2	2151-2155	MyoD	abstract	new	coref	18-30
18-3	2156-2157	—	_	_	_	_
18-4	2158-2159	a	abstract[133]	new[133]	coref	18-51[151_133]
18-5	2160-2168	myogenic	abstract[133]	new[133]	_	_
18-6	2169-2179	regulatory	abstract[133]	new[133]	_	_
18-7	2180-2186	factor	abstract[133]	new[133]	_	_
18-8	2187-2192	which	_	_	_	_
18-9	2193-2201	controls	_	_	_	_
18-10	2202-2210	skeletal	event[135]	new[135]	_	_
18-11	2211-2217	muscle	object|event[135]	new|new[135]	_	_
18-12	2218-2229	development	event[135]	new[135]	_	_
18-13	2230-2235	binds	_	_	_	_
18-14	2236-2239	CBP	object	new	_	_
18-15	2240-2243	and	_	_	_	_
18-16	2244-2252	recruits	plant[137]	new[137]	_	_
18-17	2253-2260	histone	plant[137]|abstract|object[139]	new[137]|giv|giv[139]	coref|coref|coref|coref	21-19|21-20[0_139]|21-19|21-20[0_139]
18-18	2261-2278	acetyltransferase	plant[137]|object[139]	new[137]|giv[139]	_	_
18-19	2279-2281	to	_	_	_	_
18-20	2282-2290	activate	_	_	_	_
18-21	2291-2299	myogenic	event[140]	new[140]	_	_
18-22	2300-2307	program	event[140]	new[140]	_	_
18-23	2308-2309	.	_	_	_	_
18-24	2310-2313	Cao	person	new	_	_
18-25	2314-2316	et	_	_	_	_
18-26	2317-2320	al.	_	_	_	_
18-27	2321-2327	showed	_	_	_	_
18-28	2328-2332	that	_	_	_	_
18-29	2333-2335	of	_	_	_	_
18-30	2336-2340	MyoD	abstract	giv	_	_
18-31	2341-2347	modify	_	_	_	_
18-32	2348-2351	the	abstract[145]	new[145]	_	_
18-33	2352-2361	myoblasts	abstract|abstract[145]	new|new[145]	_	_
18-34	2362-2371	chromatin	substance|abstract[145]	giv|new[145]	coref	18-56
18-35	2372-2381	structure	abstract[145]	new[145]	_	_
18-36	2382-2385	and	_	_	_	_
18-37	2386-2399	accessibility	abstract	new	coref	18-56[153_0]
18-38	2400-2401	.	_	_	_	_
18-39	2402-2407	ASCL1	person	new	appos	18-41[149_0]
18-40	2408-2409	(	_	_	_	_
18-41	2410-2415	class	abstract[148]|person[149]	giv[148]|giv[149]	coref|coref	23-8[198_148]|23-8[198_148]
18-42	2416-2418	II	abstract[148]|person[149]	giv[148]|giv[149]	_	_
18-43	2419-2420	,	person[149]	giv[149]	_	_
18-44	2421-2426	Table	person[149]|object[150]	giv[149]|giv[150]	coref	19-8[0_150]
18-45	2427-2428	1	person[149]|object[150]	giv[149]|giv[150]	_	_
18-46	2429-2430	)	_	_	_	_
18-47	2431-2434	was	_	_	_	_
18-48	2435-2440	shown	_	_	_	_
18-49	2441-2443	to	_	_	_	_
18-50	2444-2446	be	_	_	_	_
18-51	2447-2448	a	abstract[151]	giv[151]	coref	19-15[160_151]
18-52	2449-2456	pioneer	abstract[151]	giv[151]	_	_
18-53	2457-2463	factor	abstract[151]	giv[151]	_	_
18-54	2464-2469	which	_	_	_	_
18-55	2470-2478	promotes	_	_	_	_
18-56	2479-2488	chromatin	abstract|abstract[153]	giv|giv[153]	coref|coref	18-60|18-60
18-57	2489-2502	accessibility	abstract[153]	giv[153]	_	_
18-58	2503-2506	and	_	_	_	_
18-59	2507-2514	enables	_	_	_	_
18-60	2515-2524	chromatin	substance	giv	_	_
18-61	2525-2532	binding	_	_	_	_
18-62	2533-2535	by	_	_	_	_
18-63	2536-2542	others	person	new	_	_
18-64	2543-2546	TFs	abstract	giv	coref	24-14[208_0]
18-65	2547-2548	.	_	_	_	_

#Text=Recently , also AHR ( bHLH-PAS , Table 1 ) was suggested to be a pioneer factor which regulates DNA methylation during embryonic developments in unknown way .
19-1	2549-2557	Recently	_	_	_	_
19-2	2558-2559	,	_	_	_	_
19-3	2560-2564	also	_	_	_	_
19-4	2565-2568	AHR	abstract	new	appos	19-6[158_0]
19-5	2569-2570	(	_	_	_	_
19-6	2571-2579	bHLH-PAS	abstract[158]	giv[158]	_	_
19-7	2580-2581	,	abstract[158]	giv[158]	_	_
19-8	2582-2587	Table	abstract[158]|abstract	giv[158]|giv	coref	21-15
19-9	2588-2589	1	abstract[158]	giv[158]	_	_
19-10	2590-2591	)	_	_	_	_
19-11	2592-2595	was	_	_	_	_
19-12	2596-2605	suggested	_	_	_	_
19-13	2606-2608	to	_	_	_	_
19-14	2609-2611	be	_	_	_	_
19-15	2612-2613	a	abstract[160]	giv[160]	coref	27-28[231_160]
19-16	2614-2621	pioneer	abstract[160]	giv[160]	_	_
19-17	2622-2628	factor	abstract[160]	giv[160]	_	_
19-18	2629-2634	which	_	_	_	_
19-19	2635-2644	regulates	_	_	_	_
19-20	2645-2648	DNA	substance|abstract[162]	new|new[162]	coref|coref	24-6[205_0]|24-6[205_0]
19-21	2649-2660	methylation	abstract[162]	new[162]	_	_
19-22	2661-2667	during	_	_	_	_
19-23	2668-2677	embryonic	event[163]	new[163]	_	_
19-24	2678-2690	developments	event[163]	new[163]	_	_
19-25	2691-2693	in	event[163]	new[163]	_	_
19-26	2694-2701	unknown	event[163]|abstract[164]	new[163]|new[164]	coref	25-13[212_164]
19-27	2702-2705	way	event[163]|abstract[164]	new[163]|new[164]	_	_
19-28	2706-2707	.	_	_	_	_

#Text=In clear cell renal cell carcinoma ( ccRCC ) , the most frequent mutation causes the von Hippel-Lindau ( VHL ) tumor suppressor inactivation leading to genome-wide enhancer and super-enhancer remodeling .
20-1	2708-2710	In	_	_	_	_
20-2	2711-2716	clear	abstract[166]|object[168]	new[166]|new[168]	_	_
20-3	2717-2721	cell	place|abstract[166]|object[168]	giv|new[166]|new[168]	coref	20-5
20-4	2722-2727	renal	abstract[166]|object[168]	new[166]|new[168]	_	_
20-5	2728-2732	cell	place|object[168]	giv|new[168]	coref	28-24
20-6	2733-2742	carcinoma	object[168]	new[168]	_	_
20-7	2743-2744	(	_	_	_	_
20-8	2745-2750	ccRCC	place	new	_	_
20-9	2751-2752	)	_	_	_	_
20-10	2753-2754	,	_	_	_	_
20-11	2755-2758	the	abstract[170]	new[170]	_	_
20-12	2759-2763	most	abstract[170]	new[170]	_	_
20-13	2764-2772	frequent	abstract[170]	new[170]	_	_
20-14	2773-2781	mutation	abstract[170]	new[170]	_	_
20-15	2782-2788	causes	_	_	_	_
20-16	2789-2792	the	person[171]	new[171]	_	_
20-17	2793-2796	von	person[171]	new[171]	_	_
20-18	2797-2810	Hippel-Lindau	person[171]	new[171]	_	_
20-19	2811-2812	(	_	_	_	_
20-20	2813-2816	VHL	abstract	new	_	_
20-21	2817-2818	)	_	_	_	_
20-22	2819-2824	tumor	abstract|event[175]	new|new[175]	_	_
20-23	2825-2835	suppressor	object|event[175]	new|new[175]	_	_
20-24	2836-2848	inactivation	event[175]	new[175]	_	_
20-25	2849-2856	leading	_	_	_	_
20-26	2857-2859	to	_	_	_	_
20-27	2860-2871	genome-wide	abstract[176]	new[176]	_	_
20-28	2872-2880	enhancer	abstract[176]	new[176]	_	_
20-29	2881-2884	and	_	_	_	_
20-30	2885-2899	super-enhancer	event[177]	new[177]	_	_
20-31	2900-2910	remodeling	event[177]	new[177]	_	_
20-32	2911-2912	.	_	_	_	_

#Text=This process is mediated by the interaction of HIF2α and HIF1β ( bHLH-PAS , Table 1 ) with histone acetyltransferase p300 .
21-1	2913-2917	This	event[178]	new[178]	_	_
21-2	2918-2925	process	event[178]	new[178]	_	_
21-3	2926-2928	is	_	_	_	_
21-4	2929-2937	mediated	_	_	_	_
21-5	2938-2940	by	_	_	_	_
21-6	2941-2944	the	abstract[179]	giv[179]	appos	21-12[182_179]
21-7	2945-2956	interaction	abstract[179]	giv[179]	_	_
21-8	2957-2959	of	abstract[179]	giv[179]	_	_
21-9	2960-2965	HIF2α	abstract[179]|abstract	giv[179]|new	_	_
21-10	2966-2969	and	abstract[179]	giv[179]	_	_
21-11	2970-2975	HIF1β	abstract[179]|abstract	giv[179]|new	_	_
21-12	2976-2977	(	abstract[182]	giv[182]	coref	22-5[0_182]
21-13	2978-2986	bHLH-PAS	abstract[182]	giv[182]	_	_
21-14	2987-2988	,	abstract[182]	giv[182]	_	_
21-15	2989-2994	Table	abstract[182]|abstract	giv[182]|giv	coref	22-9
21-16	2995-2996	1	abstract[182]	giv[182]	_	_
21-17	2997-2998	)	abstract[182]	giv[182]	_	_
21-18	2999-3003	with	abstract[182]	giv[182]	_	_
21-19	3004-3011	histone	abstract[182]|abstract|place[186]	giv[182]|giv|new[186]	coref|coref	22-16|22-16
21-20	3012-3029	acetyltransferase	abstract[182]|object|place[186]	giv[182]|giv|new[186]	_	_
21-21	3030-3034	p300	abstract[182]|place[186]	giv[182]|new[186]	_	_
21-22	3035-3036	.	_	_	_	_

#Text=CLOCK , the other bHLH-PAS subfamily member ( Table 1 ) was shown to mediate histone acetylation in a circadian time-specific manner .
22-1	3037-3042	CLOCK	object	new	_	_
22-2	3043-3044	,	_	_	_	_
22-3	3045-3048	the	person[189]	new[189]	appos	22-9[191_189]
22-4	3049-3054	other	person[189]	new[189]	_	_
22-5	3055-3063	bHLH-PAS	abstract|person[189]	giv|new[189]	_	_
22-6	3064-3073	subfamily	person[189]	new[189]	_	_
22-7	3074-3080	member	person[189]	new[189]	_	_
22-8	3081-3082	(	_	_	_	_
22-9	3083-3088	Table	abstract|abstract[191]	giv|giv[191]	coref|coref	23-3[197_191]|23-3[197_191]
22-10	3089-3090	1	abstract[191]	giv[191]	_	_
22-11	3091-3092	)	_	_	_	_
22-12	3093-3096	was	_	_	_	_
22-13	3097-3102	shown	_	_	_	_
22-14	3103-3105	to	_	_	_	_
22-15	3106-3113	mediate	_	_	_	_
22-16	3114-3121	histone	abstract|abstract[193]	giv|new[193]	coref|coref	24-11|24-11
22-17	3122-3133	acetylation	abstract[193]	new[193]	_	_
22-18	3134-3136	in	_	_	_	_
22-19	3137-3138	a	abstract[194]	new[194]	_	_
22-20	3139-3148	circadian	abstract[194]	new[194]	_	_
22-21	3149-3162	time-specific	abstract[194]	new[194]	_	_
22-22	3163-3169	manner	abstract[194]	new[194]	_	_
22-23	3170-3171	.	_	_	_	_

#Text=Interestingly , the bHLH-O proteins members ( class VI , Table 1 ) HEY proteins can function as transcription repressors as well as transcription activators .
23-1	3172-3185	Interestingly	_	_	_	_
23-2	3186-3187	,	_	_	_	_
23-3	3188-3191	the	person[197]	giv[197]	ana	24-1[0_197]
23-4	3192-3198	bHLH-O	event|person[197]	new|giv[197]	_	_
23-5	3199-3207	proteins	substance|person[197]	giv|giv[197]	coref	23-14[201_0]
23-6	3208-3215	members	person[197]	giv[197]	_	_
23-7	3216-3217	(	_	_	_	_
23-8	3218-3223	class	abstract[198]	giv[198]	_	_
23-9	3224-3226	VI	abstract[198]|person	giv[198]|new	_	_
23-10	3227-3228	,	_	_	_	_
23-11	3229-3234	Table	_	_	_	_
23-12	3235-3236	1	_	_	_	_
23-13	3237-3238	)	_	_	_	_
23-14	3239-3242	HEY	abstract|substance[201]	new|giv[201]	coref|coref|coref|coref	25-9|28-10[235_201]|25-9|28-10[235_201]
23-15	3243-3251	proteins	substance[201]	giv[201]	_	_
23-16	3252-3255	can	_	_	_	_
23-17	3256-3264	function	_	_	_	_
23-18	3265-3267	as	_	_	_	_
23-19	3268-3281	transcription	abstract	giv	coref	23-24
23-20	3282-3292	repressors	_	_	_	_
23-21	3293-3295	as	_	_	_	_
23-22	3296-3300	well	_	_	_	_
23-23	3301-3303	as	_	_	_	_
23-24	3304-3317	transcription	abstract	giv	coref	27-8
23-25	3318-3328	activators	_	_	_	_
23-26	3329-3330	.	_	_	_	_

#Text=They were shown to bind directly DNA and interact with histone deacetylases and other TFs .
24-1	3331-3335	They	person	giv	_	_
24-2	3336-3340	were	_	_	_	_
24-3	3341-3346	shown	_	_	_	_
24-4	3347-3349	to	_	_	_	_
24-5	3350-3354	bind	_	_	_	_
24-6	3355-3363	directly	substance[205]	giv[205]	_	_
24-7	3364-3367	DNA	substance[205]	giv[205]	_	_
24-8	3368-3371	and	_	_	_	_
24-9	3372-3380	interact	_	_	_	_
24-10	3381-3385	with	_	_	_	_
24-11	3386-3393	histone	abstract|abstract[207]	giv|new[207]	_	_
24-12	3394-3406	deacetylases	abstract[207]	new[207]	_	_
24-13	3407-3410	and	_	_	_	_
24-14	3411-3416	other	abstract[208]	giv[208]	coref	27-4[222_208]
24-15	3417-3420	TFs	abstract[208]	giv[208]	_	_
24-16	3421-3422	.	_	_	_	_

#Text=On the other hand , gene activation by HEY is regulated in an indirect way .
25-1	3423-3425	On	_	_	_	_
25-2	3426-3429	the	_	_	_	_
25-3	3430-3435	other	_	_	_	_
25-4	3436-3440	hand	_	_	_	_
25-5	3441-3442	,	_	_	_	_
25-6	3443-3447	gene	abstract|abstract[210]	new|new[210]	_	_
25-7	3448-3458	activation	abstract[210]	new[210]	_	_
25-8	3459-3461	by	abstract[210]	new[210]	_	_
25-9	3462-3465	HEY	abstract[210]|abstract	new[210]|giv	coref	26-2
25-10	3466-3468	is	_	_	_	_
25-11	3469-3478	regulated	_	_	_	_
25-12	3479-3481	in	_	_	_	_
25-13	3482-3484	an	abstract[212]	giv[212]	_	_
25-14	3485-3493	indirect	abstract[212]	giv[212]	_	_
25-15	3494-3497	way	abstract[212]	giv[212]	_	_
25-16	3498-3499	.	_	_	_	_

#Text=Multiple HEY binding sites located downstream and close to the transcriptional start site , resulted in a hypothesis that HEY influence the pausing/elongation switch of Pol II .
26-1	3500-3508	Multiple	place[214]	new[214]	_	_
26-2	3509-3512	HEY	abstract|place[214]	giv|new[214]	_	_
26-3	3513-3520	binding	place[214]	new[214]	_	_
26-4	3521-3526	sites	place[214]	new[214]	_	_
26-5	3527-3534	located	_	_	_	_
26-6	3535-3545	downstream	place	new	_	_
26-7	3546-3549	and	_	_	_	_
26-8	3550-3555	close	_	_	_	_
26-9	3556-3558	to	_	_	_	_
26-10	3559-3562	the	place[217]	new[217]	_	_
26-11	3563-3578	transcriptional	place[217]	new[217]	_	_
26-12	3579-3584	start	event|place[217]	new|new[217]	_	_
26-13	3585-3589	site	place[217]	new[217]	_	_
26-14	3590-3591	,	_	_	_	_
26-15	3592-3600	resulted	_	_	_	_
26-16	3601-3603	in	_	_	_	_
26-17	3604-3605	a	abstract[218]	new[218]	_	_
26-18	3606-3616	hypothesis	abstract[218]	new[218]	_	_
26-19	3617-3621	that	_	_	_	_
26-20	3622-3625	HEY	_	_	_	_
26-21	3626-3635	influence	_	_	_	_
26-22	3636-3639	the	object[220]	new[220]	_	_
26-23	3640-3658	pausing/elongation	abstract|object[220]	new|new[220]	_	_
26-24	3659-3665	switch	object[220]	new[220]	_	_
26-25	3666-3668	of	object[220]	new[220]	_	_
26-26	3669-3672	Pol	object[220]|person[221]	new[220]|giv[221]	_	_
26-27	3673-3675	II	object[220]|person[221]	new[220]|giv[221]	_	_
26-28	3676-3677	.	_	_	_	_

#Text=Interestingly , though most of TFs stimulate transcription initiation , MYC ( class III , Table 1 ) was shown to stimulate transcription elongation by recruitment of the elongation factor .
27-1	3678-3691	Interestingly	_	_	_	_
27-2	3692-3693	,	_	_	_	_
27-3	3694-3700	though	_	_	_	_
27-4	3701-3705	most	abstract[222]	giv[222]	_	_
27-5	3706-3708	of	abstract[222]	giv[222]	_	_
27-6	3709-3712	TFs	abstract[222]	giv[222]	_	_
27-7	3713-3722	stimulate	_	_	_	_
27-8	3723-3736	transcription	abstract|event[224]	giv|new[224]	coref|coref	27-23|27-23
27-9	3737-3747	initiation	event[224]	new[224]	_	_
27-10	3748-3749	,	_	_	_	_
27-11	3750-3753	MYC	abstract	new	appos	27-13[226_0]
27-12	3754-3755	(	_	_	_	_
27-13	3756-3761	class	abstract[226]	giv[226]	_	_
27-14	3762-3765	III	abstract[226]	giv[226]	_	_
27-15	3766-3767	,	_	_	_	_
27-16	3768-3773	Table	_	_	_	_
27-17	3774-3775	1	_	_	_	_
27-18	3776-3777	)	_	_	_	_
27-19	3778-3781	was	_	_	_	_
27-20	3782-3787	shown	_	_	_	_
27-21	3788-3790	to	_	_	_	_
27-22	3791-3800	stimulate	_	_	_	_
27-23	3801-3814	transcription	abstract|event[228]	giv|new[228]	coref|coref	27-29[0_228]|27-29[0_228]
27-24	3815-3825	elongation	event[228]	new[228]	_	_
27-25	3826-3828	by	_	_	_	_
27-26	3829-3840	recruitment	abstract[229]	new[229]	_	_
27-27	3841-3843	of	abstract[229]	new[229]	_	_
27-28	3844-3847	the	abstract[229]|abstract[231]	new[229]|giv[231]	_	_
27-29	3848-3858	elongation	abstract[229]|event|abstract[231]	new[229]|giv|giv[231]	_	_
27-30	3859-3865	factor	abstract[229]|abstract[231]	new[229]|giv[231]	_	_
27-31	3866-3867	.	_	_	_	_

#Text=The presented studies indicate that the crucial role of the bHLH proteins in maintaining transcriptional regulation of important developmental ( e. g. , cell differentiation ) and oncogenic pathways is dependent on the multiple interactions with basal transcriptional machinery .
28-1	3868-3871	The	abstract[232]	new[232]	_	_
28-2	3872-3881	presented	abstract[232]	new[232]	_	_
28-3	3882-3889	studies	abstract[232]	new[232]	_	_
28-4	3890-3898	indicate	_	_	_	_
28-5	3899-3903	that	_	_	_	_
28-6	3904-3907	the	abstract[233]	new[233]	_	_
28-7	3908-3915	crucial	abstract[233]	new[233]	_	_
28-8	3916-3920	role	abstract[233]	new[233]	_	_
28-9	3921-3923	of	abstract[233]	new[233]	_	_
28-10	3924-3927	the	abstract[233]|substance[235]	new[233]|giv[235]	_	_
28-11	3928-3932	bHLH	abstract[233]|abstract|substance[235]	new[233]|giv|giv[235]	_	_
28-12	3933-3941	proteins	abstract[233]|substance[235]	new[233]|giv[235]	_	_
28-13	3942-3944	in	_	_	_	_
28-14	3945-3956	maintaining	_	_	_	_
28-15	3957-3972	transcriptional	abstract[236]	new[236]	_	_
28-16	3973-3983	regulation	abstract[236]	new[236]	_	_
28-17	3984-3986	of	abstract[236]	new[236]	_	_
28-18	3987-3996	important	abstract[236]	new[236]	_	_
28-19	3997-4010	developmental	abstract[236]	new[236]	_	_
28-20	4011-4012	(	_	_	_	_
28-21	4013-4015	e.	_	_	_	_
28-22	4016-4018	g.	_	_	_	_
28-23	4019-4020	,	_	_	_	_
28-24	4021-4025	cell	place|event[238]	giv|new[238]	_	_
28-25	4026-4041	differentiation	event[238]	new[238]	_	_
28-26	4042-4043	)	_	_	_	_
28-27	4044-4047	and	_	_	_	_
28-28	4048-4057	oncogenic	abstract|place[240]	new|new[240]	_	_
28-29	4058-4066	pathways	place[240]	new[240]	_	_
28-30	4067-4069	is	_	_	_	_
28-31	4070-4079	dependent	_	_	_	_
28-32	4080-4082	on	_	_	_	_
28-33	4083-4086	the	abstract[241]	giv[241]	_	_
28-34	4087-4095	multiple	abstract[241]	giv[241]	_	_
28-35	4096-4108	interactions	abstract[241]	giv[241]	_	_
28-36	4109-4113	with	abstract[241]	giv[241]	_	_
28-37	4114-4119	basal	abstract[241]|abstract[242]	giv[241]|new[242]	_	_
28-38	4120-4135	transcriptional	abstract[241]|abstract[242]	giv[241]|new[242]	_	_
28-39	4136-4145	machinery	abstract[241]|abstract[242]	giv[241]|new[242]	_	_
28-40	4146-4147	.	_	_	_	_
